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Background and purpose   Most lung cancer patients with skeletal 
metastases have a short survival and it is difficult to identify those 
patients who will benefit from palliative surgery. We report com-
plication and survival rates in a consecutive series of lung cancer 
patients who were operated for symptomatic skeletal metastases.
Methods      This  study  was  based  on  data  recorded  in  the 
Karolinska Skeletal Metastasis Register. The study period was 
1987–2006. We identified 98 lung cancer patients (52 females). 
The median age at surgery was 62 (34–88) years. 78 lesions were 
located in the femur or spine.
Results   The median survival time after surgery was 3 (0–127) 
months.  The  cumulative  12-month  survival  after  surgery  was 
13% (95% CI: 6–20). There was a difference between the survival 
after spinal surgery (2 months) and after extremity surgery (4 
months) (p = 0.03). Complete pathological fracture in non-spinal 
metastases (50 patients) was an independent negative predictor of 
survival (hazard ratio (HR) = 1.8, 95% CI: 1–3). 16 of 31 patients 
with spinal metastases experienced a considerable improvement 
in their neurological function after surgery. The overall complica-
tion rate was 20%, including a reoperation rate of 15%.
Interpretation   Bone metastases and their subsequent surgical 
treatment in lung cancer patients are associated with high mor-
bidity and mortality. Our findings will help to set appropriate 
expectations for these patients, their families, and surgeons.
 
Lung cancer has become one of the most common cancers 
worldwide  and  is  the  predominant  cause  of  death  among 
cancer patients. The American Cancer Society estimated that 
almost 160,000 patients would die from lung and bronchus 
cancer in the USA in 2009 (Jemal et al. 2009). Some authors 
have stated that lung cancer is one of the most important chal-
lenges in oncology at the present time (Boyle and Dresler 
2005).
Historically, about one third of all lung cancer patients are 
found to have bone metastases during the course of the dis-
ease. Symptoms and events of skeletal origin such as pain, 
pathological  fractures,  spinal  cord  compression  with  para-
paresis, and hypercalcemia are common complications. The 
decline in quality of life and eventual death of these patients 
can be explained to some extent by skeletal complications and 
their treatment (Coleman 1997).
Lung  cancer  patients  with  skeletal  events  have  a  short 
expected survival; however, some case reports have involved 
patients who survived several years after pathological frac-
tures (Agarwala and Hanna 2005, Hirano et al. 2005). A major 
problem in selecting patients for surgery is to avoid operat-
ing on those who are likely to die very soon after surgery. 
Although several features help to identify patients with long 
survival (Bauer and Wedin 1995, Tomita et al. 2001), it is still 
difficult to identify those who will die early.
We analyzed a consecutive series of lung cancer patients 
who were operated on for skeletal metastases at our depart-
ment, to determine the complications and reoperation rates 
after surgery and to identify risk factors for early death.
Patients and methods
This study was based on data recorded in the Karolinska Skel-
etal Metastasis Register (Wedin and Bauer 2005). The reg-
ister is a quality-control database that prospectively collects 
individual-based information for cancer patients admitted to 
Karolinska University Hospital in Stockholm. All data are col-
lected based on the national registration number (a 10-digit 
number), which is unique for each Swedish resident. The cri-
terion for inclusion in the database is surgical treatment for 
complete or impending fractures due to skeletal metastasis. 
The register gathers data on patient identity, age, sex, pri-
mary  tumor,  location  of  metastases,  type  of  pathological 
fracture, and surgical treatment such as method of fixation, 
type of implant, and postoperative complications. It includes 
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(Mountain  1997).  Neurological  function  in  patients  with 
spinal metastases is assessed by the Frankel classification of 
motor and sensory compromise (Frankel et al. 1969, Davis et 
al. 1993). The neurological function is assessed preoperatively 
and within 2 weeks postoperatively.
For the present study, we included all lung cancer patients 
who had surgery due to pathological fractures. None of the 
patients were excluded for any reason. In patients who had 
surgery for more than 1 metastasis, all sites were included in 
the analysis. However, only the first surgical procedure was 
accounted for in the survival analysis. The study period was 
1987–2006.
We identified 98 individual lung cancer patients (52 females) 
treated surgically for skeletal metastatic lesions. The median 
age at surgery was 62 (34–88) years. Most patients in this 
cohort (n = 88) were current or former smokers at diagnosis of 
the disease. Adenocarcinoma was found in most cases (n = 58) 
followed by squamous cell carcinoma (n = 14) (Table 1). The 
lung cancer patients were grouped in the following stages: 11 
IA + IB, 1 IIA + IIB, 5 IIIA, 73 IIIB + IV, and such data were 
missing for 8 patients.
Statistics
Median values and ranges were used as descriptive statistics. 
Kaplan-Meier  analysis  was  used  to  construct  the  cumula-
tive survival with 95% confidence intervals (CIs). The time 
between diagnosis of lung cancer and death and time between 
surgical procedure and death were included in the survival 
analysis. The log-rank test was used to compare survival after 
extremity surgery with spine surgery.
The Cox multiple-regression model was used to study risk 
factors for death related to the patient and to the surgical pro-
cedure. The results were expressed as hazard ratios (HRs) with 
corresponding 95% CI. If a HR was > 1, the patients at risk 
were dying at a faster rate than the patients in the reference 
group. The assumption of proportional hazards was investi-
gated by hazard function plots and log-log plots for all covari-
ates. No signs of insufficient proportionality were detected in 
the hazard functions and the log-log plots ran parallel for all 
covariates. The factors studied in the univariate Cox model 
were as follows: age, sex, smoking status, type of lung cancer, 
staging, location of skeletal metastasis, type of pathological 
fracture, preoperative hemoglobin levels, time period of sur-
gery (1987–1996 vs. 1997–2006) and perioperative chemo- 
and radiotherapy (Table 1). Any variable whose univariate test 
had a p-value of < 0.25 was considered as a candidate for the 
multivariate model along with all variables of known biologi-
cal importance. Wilcoxon’s signed ranks test was used to com-
pare preoperative and postoperative neurological function in 
patients with spine metastases. The level of significance was 
set at p ≤ 0.05. All statistical analyses were performed using 
the PASW statistics package version 18 (SPSS Inc., Chicago, 
IL).
Results
Most metastatic bone lesions were located in the femur and 
vertebra. Of the 31 vertebral lesions, 22 were located in the 
thoracic spine and 9 in the lumbar spine. 53 of 70 non-spinal 
lesions had caused complete pathological fractures. Regarding 
treatment of the primary tumor, more than half of the patients 
(n = 52) had chemotherapy and 27 had radiotherapy. Postop-
erative radiotherapy for the operated lesions was registered in 
59 patients (Table 1). None of the patients were lost to follow-
up, and none were still alive at the time of this analysis.
The neurological function in patients with spine metasta-
ses improved after surgery (p = 0.001). 16 of the 31 patients 
gained at least 1 Frankel grade, 14 maintained their neurologi-
cal function, and 1 patient deteriorated (Table 2). The main 
indication for surgery in these patients was spinal cord com-
pression (n = 29) or painful instability (n = 2).
Survival analysis
The median survival time after surgery of skeletal metastatic 
lesions was 3 (0–127) months. Males had a median survival 
Table 1. 98 lung cancer patients with skeletal metastases 
   
  Total  Males  Females
Number of patients  98  46  52
Median age at diagnosis (years)  62  60  63
   range  34–88  43–88  34–84
Smoking status at diagnosis     
  Former smoker  47  21  26
  Current smoker  41  20  21
  Never smoker  10    5    5
Histopathology     
  Non-small cell cancer     
     Adenocarcinoma  58  25  33
     Squamous cell carcinoma  14    8    6
     Low differentiated 
       non-small cell cancer    8    4    4
      Large cell carcinoma    7    3    4
  Small cell cancer    6    3    3
  Other cancers    5    3    2
Skeletal metastasis     
  Femur  46  18  28
  Vertebra  31  24    7
  Humerus  16  2  14
  Other    8  2    6
Type of surgical procedure     
  Internal fixation  34  10  24
  Endoprosthesis  32  11  21
  Spinal decompression 
     + instrumentation  17  12    5
  Spinal decompression  15  12    3
  Other    3    1    2
Preoperative treatment (primary tumor)     
  Chemotherapy  52  24  28
  Radiotherapy  27  10  17
  Lobectomy  12    5    7
Postoperative treatment 
  (bone metastasis)     
  Radiotherapy  59  28  3198  Acta Orthopaedica 2011; 82 (1): 96–101
time of 2 (0–59) and females of 4 (0–127) months (Table 3). 
The cumulative 6-, 12-, and 18-month survival after surgery 
was 24% (CI: 15–33), 13% (CI: 6–20), and 6% (1–11) respec-
tively (Figure).
There was a difference between the median survival time 
after spinal surgery (2 (0–15) months) and after extremity sur-
gery (4 (0–127) months) (p = 0.03) (Table 3).
The univariate Cox regression analysis revealed an increased 
risk of death after surgery for patients with complete patholog-
ical fracture, metastatic lesions in the vertebra, preoperative 
hemoglobin levels less than 10 g/dL, small cell cancer, and the 
absence of postoperative radiotherapy. The multivariate Cox 
analysis with the above 5 variables and age and sex showed 
that complete pathological fracture was a significant predictor 
of survival (Table 4). All the other factors studied—such as 
age, sex, smoking status, staging, time period of surgery, and 
chemotherapy—were not associated with an increased risk of 
death.
Reoperations and complications 
The  overall  complication  rate  including  reoperations  was 
20/98. 15 failed reconstructions in 14 patients led to a new 
operation. The reasons for these reoperations were poor initial 
fixation, local tumor progression, periprosthetic fracture, deep 
infection, paraplegia, material failure, nonunion, and technical 
error. The median time to failure was 1 (0–13) months (Table 
5).
Complications that were treated non-surgically were seen in 
5 of the patients, including wound infection, gastric bleeding, 
poor initial fixation, and technical error (Table 6).
Table 2. Pre- and postoperative neurological func-
tion in 31 patients with spine metastasis graded 
according to Frankel 
 
  Preop.  Follow-up
A. Complete paraplegia  2  1
B. No motor function  6  2
C. Motor function useless  14  7
D. Slight motor deficit  6  16
E. No motor deficit  3  5
Cumulative survival of lung cancer patients after surgery for skeletal 
metastases, with 95% confidence intervals.
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Table  3.  Median  survival  of  lung  cancer  patients  with  skeletal 
metastases. Time in months (range) 
 
  A  B
All    10 (0–168)  3 (0–127)
  Males    8 (1–60)  2 (0–59)
  Females  10 (0–168)  4 (0–127)
Histopathology   
  Non-small cell cancer  10 (0–168)  4 (0–127)
     Adenocarcinoma  11 (1–168)  4 (0–127)
     Squamous cell carcinoma    9 (0–43)  2 (0–18)
     Low differentiated non-small 
       cell cancer    8 (1–12)  2 (0–8)
     Large cell carcinoma  11 (6–60)  7 (0–59)
  Small cell cancer    8 (1–23)  2 (0–3)
  Other cancers    5 (1–24)  1 (1–15)
Spinal surgery   
  All    7 (2–29)  2 (0–15)
  Males    7 (2–29)  2 (0–15)
  Females    8 (3–20)  1 (1–7)
Extremity surgery   
  All  10 (0–168)  4 (0–127)
  Males  10 (1–60)  3 (0–59)
  Females  11 (0–168)  4 (0–127)
Pathological fracture   
  Complete    8 (0–80)  2 (0–61)
  Impending  12 (2–168)  4 (0–127)
A: time between diagnosis of lung cancer and death; 
B: time between surgical procedure and death. 
Table 4. Risk of death after surgery for skeletal metastases in lung 
cancer patients (Cox regression analysis) 
   
Factor  HR  95% CI  p-value
Complete pathological fracture a  1.7 f  1.1–2.6  0.02
  1.8 g  1.0–3.0  0.05
Vertebral skeletal metastasis b  1.7 f  1.0–2.7  0.03
  1.7 g  0.9–3.4  0.1
Hemoglobin level < 10 g/dL c  1.9 f  1.1–3.4  0.03
  1.8 g  0.9–3.7  0.09
Small cell cancer d  2.6 f  1.2–6.0  0.02
  1.9 g  0.8–4.8  0.2
Postoperative radiotherapy (no) e  1.7 f  1.1–2.6  0.03
  1.6 g  0.9–2.9  0.1
Factor versus a impending pathological fracture, b femur, c ≥ 10 g/
dL,d adenocarcinoma, e yes; 
HR = hazard ratio, f unadjusted, g adjusted (HRs are adjusted 
for type of pathological fracture, location of skeletal metastasis, 
preoperative hemoglobin levels, type of lung cancer, postoperative 
radiotherapy, age, and sex).Acta Orthopaedica 2011; 82 (1): 96–101  99
Discussion
Our main finding was the short survival of lung cancer patients 
after surgery for skeletal metastases. Complete pathological 
fracture was identified as an independent risk factor for death. 
Moreover,  a  high  complication  rate  poses  a  considerable 
burden to the patients.
The overall median survival time after surgery was only 3 
months, and just 13% of the patients were still alive 1 year 
postoperatively.  3  of  4  patients  were  already  classified  as 
having an advanced stage of lung cancer at the diagnosis of 
the primary tumor. The 1-year survival rate of patients oper-
ated for skeletal metastases from various primary tumor sites 
is limited, and ranges between 30 and 54% (Bono et al. 1991, 
Bauer  and Wedin  1995,  Durr  and  Refior  1998,  Bohm  and 
Huber 2002, Hansen et al. 2004, Lin et al. 2007). Differences 
in patient selection, type of primary tumor, and indications for 
surgery may explain the spread in survival time. We have pre-
viously reported on the surgical outcome of 107 patients with 
skeletal breast cancer metastases. The postoperative median 
survival in these patients was 8 months (Wedin et al. 2001). 
Sugiura et al. (2008) reported a median survival time of 7 
months in 118 patients with bone metastasis from lung cancer; 
however, only one third of these patients underwent surgery. 
Nathan et al. (2005) found that in patients with various types 
of cancer metastases, lung cancer patients fared the worst with 
a median survival time of 4 months. The short survival time 
has also been reported by other authors (Bauer and Wedin 
1995, Durr and Refior 1998, Katagiri et al. 2005).
We found a shorter survival after operations for skeletal 
metastases of the spine (2 months) as compared to the extrem-
ities (4 months). Bauer and Wedin (1995) described a median 
1-year survival of 25% after spinal surgery and 31% after 
extremity surgery, based on all types of cancer metastases. 
However, this difference was not statistically significant.
The decision between a surgical and non-surgical treatment 
of a patient with bone metastasis is influenced by the anatomi-
cal location, the tumor type, the extent of the tumor, the gen-
Table 5. Reoperations after surgery for skeletal metastases in lung cancer patients
       
Sex, age,  Localization  Primary operation  Time (months) to and  Treatment
histology      reason for failure
F, 57, b  Humerus, proximal  Intramedullary nail    5, local tumor progression  Hemiarthroplasty
F, 63, c  Humerus, distal  Plate    3, material failure  Plate
F, 62, a  Acetabulum  Acetabular 
    reinforcement ring + 
    total joint arthroplasty    1, deep infection  Debridement
F, 62, a  Femur, proximal  Total joint arthroplasty    9, periprosthetic fracture  Modular tumor prosthesis
F, 74, a  Femur, proximal  Hemiarthroplasty    3, periprosthetic fracture  Modular tumor prosthesis
F, 66, a  Femur, trochanteric  Hemiarthroplasty    1, poor initial fixation  Total joint arthroplasty
M, 45, a  Femur, trochanteric  Sliding hip screw    1, poor initial fixation  Total joint arthroplasty
F, 73, b  Femur, trochanteric  Sliding hip screw    1, poor initial fixation  Exchange of screw
        4, poor bone stock  Total joint arthroplasty
F, 62, a  Femur, subtrochanteric  Hemiarthroplasty    0, technical error  Hemiarthroplasty
F, 53, a  Femur, distal  Plate  13, non-union + local 
            tumor progression  Plate
M, 56, a  Vertebra, thoracic  Decompression    0, paraplegia (hematoma)  Removal of hematoma
M, 55, d  Vertebra, thoracic  Decompression + 
    instrumentation    8, local tumor progression  Decompression
F, 48, a  Vertebra, thoracic  Decompression + 
    instrumentation    0, poor initial fixation  Reinstrumentation
M, 72, b  Vertebra, thoracic  Decompression    1, deep infection  Debridement
a adenocarcinoma. b squamous cell carcinoma. c large cell carcinoma. d other.
Table 6. Complications after surgery for skeletal metastasis in lung cancer patients
       
Sex, age,   Localization  Primary operation  Time (months) to and  Treatment
histology      reason for failure
F, 75, a  Femur, distal  Intramedullary nail  0, fatal gastric bleeding  Non-surgical
M, 48, c  Vertebra, thoracic  Decompression + instrumentation  0, wound infection  Non-surgical
F, 48, b  Vertebra, thoracic  Decompression + instrumentation  0, gastric bleeding  Non-surgical
M, 62, d  Vertebra, thoracic  Decompression + instrumentation  0, technical error  Non-surgical
M, 55, d  Vertebra, thoracic  Decompression  1, wound infection  Non-surgical
a adenocarcinoma. b large cell carcinoma. c small cell lung cancer. d other.100  Acta Orthopaedica 2011; 82 (1): 96–101
eral medical condition of the patient, and expected survival 
time. Surgery may be chosen if the patient is healthy enough 
and life expectancy is sufficiently long to benefit from pain 
relief, improved mobility, and care. If there is no expectation 
that the survival may be long enough for the patient to recover 
and truly benefit from surgical procedures, other palliative 
therapies may be chosen instead. However, this may restrict 
the patients involved to bed or chair.
New therapies have been introduced to improve the survival 
of patients with lung cancer (Giaccone et al. 2006, Sandler et 
al. 2006). The median survival of patients with advanced lung 
cancer has increased from 6 months to 12 months with the 
introduction of new treatment regimens such as chemotherapy 
in combination with a monoclonal antibody, which acts as an 
angiogenesis inhibitor (Rosen et al. 2003, Sandler et al. 2006). 
However, the efficacy of promising new agents in lung cancer 
patients concerning treatment of metastases in bone, which is 
one of the most common metastatic sites, is unknown (Langer 
and Hirsh 2010).
Some  authors  have  stated  that  a  life  expectancy  of  at 
least 2 months is usually required for meaningful surgery 
of limb metastases (Harrington et al. 1976), and of 3 to 6 
months  for  spinal  lesions  (Cybulski  et  al.  1987, Atanasiu 
et al. 1993, Tomita et al. 1994). We think that stabilization 
of long-bone fractures is almost always justified unless the 
patient has reached a terminal stage. However, we must raise 
the question of whether spinal surgery would be justified in 
our cohort with a median survival time of barely 2 months. 
Decision making regarding the management of pathological 
fractures is complex, balancing tumor biology, biomechan-
ics, and functional outcome goals. We believe that surgery for 
vertebral metastases may be the best alternative in patients 
who are expected to live for at least another 2–3 months if 
surgery leads to a substantial difference, i.e. if the patient can 
avoid being bedridden or can retain the ability to ambulate 
independently.
More than half of our patients with spine disease improved 
considerably, i.e. at least 1 Frankel grade. Still, a 2-month 
survival will be necessary in most cases to gain real benefit 
from the procedure, considering postoperative pain, surgical 
complications,  and  sometimes  slow  neurological  recovery. 
Today, we are more cautious with patient selection for surgery 
because of the short survival rate in combination with a high 
complication rate in this cohort.
We identified low preoperative hemoglobin levels as a neg-
ative predictor of survival. Hemoglobin has been used as a 
prognostic factor in metastatic prostate cancer (Matzkin et al. 
1993) and in heterogeneous groups of cancer patients (Hansen 
et al. 2004, Nathan et al. 2005). In the multivariate analysis, 
we could show that complete pathological fractures had an 
unfavorable  prognosis  for  survival,  as  described  by  other 
authors (Sugiura et al. 2008).
Almost all of the patients (14/16) with humeral metastases 
had complete fractures. This is probably because impending 
fractures in non-weight bearing bones frequently escape diag-
nosis due to the relative absence of load-related pain.
We found a complication rate of 20%. The total failure rate 
leading to reoperation of previously operated metastatic sites 
was 15%. We have previously reported a reoperation rate of 
12% in skeletal breast cancer metastases (Wedin et al. 2001) 
and a failure rate of 11% in patients treated for metastatic 
lesions of the long bones (Wedin et al. 1999). Nathan et al. 
(2005) described a similar reoperation rate (11%) after surgery 
in patients with different types of cancer. Failures are often due 
to local tumor progression, stress fracture, implant failure due 
to nonunion, or poor fixation of osteosynthetic devices in insuf-
ficient bone stock. They appear equally often in the extremities 
and in the spine (Yazawa et al. 1990, Bono et al. 1991), as in 
our series. The high reoperation rate in our study may also be 
partly explained by the fact that during the 20-year time frame, 
many orthopedic surgeons—not all sub-specialized in ortho-
pedic oncology—performed the operations.
Our  study  was  limited  by  confounding  factors.  Changes 
in diagnostics, in selection of patients, in perioperative treat-
ment, in indications for surgery, and in methods of fixation 
during  the  20-year  study  period  may  have  influenced  the 
results. To address the question of whether or not to operate 
on lung cancer patients with bone metastases, one would want 
to know the survival prognosis for all patients—not only the 
ones who (historically) have undergone surgery—as they rep-
resent a selected group of patients. This could not be investi-
gated, however, as our register covers only surgically-treated 
cancer patients.
Despite its shortcomings, the present work represents the 
largest follow-up study of lung cancer patients after surgery 
for skeletal metastases. Most studies have analyzed hetero-  studies have analyzed hetero-
geneous populations of patients with bone metastasis. Most 
analyses on indications for surgery have been based on the 
treatment of breast and prostate cancer, which is not necessar-
ily applicable to lung cancer patients.
In conclusion, our findings highlight the fact that surgical 
treatment of bone metastases in lung cancer patients is asso-
ciated with high morbidity and mortality. Thus, the selection 
process for the (probably) few lung cancer patients who will 
benefit from surgical treatment is important, especially those 
with spinal cord compression.
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